Date: 2016-11-15
Type of information: Licensing agreement
Compound: interferon alpha manufacturing license
Company: Neovacs (France) Amegabiotech (Argentina)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On November 15, 2016, Neovacs announced an agreement with the Argentinean company Amegabiotech to acquire its Interferon Alpha manufacturing license. IFNalpha is a key component of Neovacs’ lead therapeutic candidate, IFNalpha Kinoid, which is composed of inactivated IFNalpha coupled with a carrier protein, keyhole limpet hemocyanin.
Financial terms:
Latest news:
